Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04097431 · ClinicalTrials.gov registry record · NA

Identifying Precursors to Severe Problem Behavior

A NA study of Aggression and Problem Behavior, sponsored by Hugo W. Moser Research Institute at Kennedy Krieger.

Completed
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT04097431: Completed NA study of Aggression and Problem Behavior, sponsored by Hugo W. Moser Research Institute at Kennedy Krieger.

NCT04097431 is a NA study of Aggression and Problem Behavior that has completed, run by Hugo W. Moser Research Institute at Kennedy Krieger. The registered enrollment target is 30 participants, below the 154-participant average among 21 other Aggression trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04097431, a NA study of Aggression and Problem Behavior, has completed, sponsored by Hugo W. Moser Research Institute at Kennedy Krieger.

COMPLETED
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

The primary objective of this research is to evaluate the escalating sequence of behavior that culminates in severe problem behavior (SPB, such as aggression, self-injury, and disruption). To do so, we will investigate the precursors of SPB, which are defined as behaviors that are not as severe or dangerous as SPB, but that reliably precede the occurrence of SPB. Identifying and knowing about these precursors has the potential to complement existing behavioral treatments, making treatments safer (because SPB may occur to a lesser extent or not at all). However, existing research on precursors has been opportunistic and lacks systematic study. This research will examine methods to identify and better understand precursors.

Primary Outcome

Data on topographies of SPB (e.g., aggression, disruptions) will be collected in real time using direct observation of the behavior. Data will be collected on the frequency of problem behavior which will be transformed into responses per minute. Data will be collected during baseline (no blocking) and treatment phase (blocking). The outcome measure for SPB will be the percentage change during treatment relative to baseline.

Interventions

  • BEHAVIORAL Response Blocking

Study Locations (1)

Maryland

  • Kennedy Krieger Institute - Baltimore

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2019-10-07
Est. Completion 2021-09-30
Phase NA

What the finished NCT04097431 record still lists

NCT04097431 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 154-participant average among 21 other Aggression trials with a reported enrollment target (81% lower).

The record links to 2 conditions, with Aggression appearing as the primary indexed condition, and to 1 intervention - of which Response Blocking is the first listed.

NCT04097431 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT04097431 about?

NCT04097431 is a clinical study titled "Identifying Precursors to Severe Problem Behavior". The primary objective of this research is to evaluate the escalating sequence of behavior that culminates in severe problem behavior (SPB, such as aggression, self-injury, and disruption). To do so, we will investigate the precursors of SPB, which are defined as behaviors that are not as severe or d...

What is the current status of trial NCT04097431?

This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2019-10-07. Estimated completion is 2021-09-30.

What conditions does trial NCT04097431 study?

This clinical trial studies the following conditions: Aggression, Problem Behavior.

What interventions are being tested in trial NCT04097431?

The interventions under investigation include: Response Blocking (BEHAVIORAL).

Who is sponsoring clinical trial NCT04097431?

This trial is sponsored by Hugo W. Moser Research Institute at Kennedy Krieger, which has 73 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04097431 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Aggression

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04097431's enrollment target sits among peer trials

30 17th of 21 higher than 3 of 21 other Aggression trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Aggression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04097431, the US trial registry maintained by the National Library of Medicine. NCT04097431 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.